{"name":"Neurelis, Inc.","slug":"neurelis-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NRL-1","genericName":"NRL-1","slug":"nrl-1","indication":"Acute repetitive seizures (clusters)","status":"phase_3"}]}],"pipeline":[{"name":"NRL-1","genericName":"NRL-1","slug":"nrl-1","phase":"phase_3","mechanism":"NRL-1 is a neuroactive steroid that enhances GABAergic inhibitory neurotransmission in the central nervous system.","indications":["Acute repetitive seizures (clusters)","Status epilepticus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQWHlXNjFfVjN1b0pQNVN0cXFhb0RaSzNzMW9PckRYUEI4WlVTUmdON09ZODgxbFU3eU1MYjZUVzZpNTlJdm5UU3ZkU21iekFtaGZLWlRlU2tTbjRqdmFtdURMRXg4T1ZiU1VBLW5QVDg4U3Rnem1nbnZyUm50VlFFd2xabmVKMDVsN2xqcHhxSVN5dzNmMUpBbkhVdWtlSEtHeFRJ0gFYQVVfeXFMTkdKZmlfVFBPTlVwZ0JHMUVxLWh3NHlzRWszNWYtWU01b3lsc3J4RkNVaDU4U3pjZV9sQ0RWa1ZKNUdHbWVTODdPQXpZVlpCVEZJWlhuakJNcQ?oc=5","date":"2026-03-25","type":"pipeline","source":"Law360","summary":"New Orphan Drug Law Provides A Key Fix For Pharma Cos. - Law360","headline":"New Orphan Drug Law Provides A Key Fix For Pharma Cos. - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNV2VkMzJUdTNoeHNIbnFVZHlEckd1dUhmWHBuTzR4VGFKNEtFYV9EaGMxOFJoM1NXTEt6Y3I2c1JTaDVoWk9fSmtRNktXMnRoU2tscXZFbWE5SEh1dzJ0dDdmWk8xM3RnREozQlBMYUt3VVBxUW5JVmtUeGpHWTNpN0xvZjJZdTdBVWV2YUhxWmNMYkhGN2R3V0llNVk0Rk5sVzV6c2lIakVWQ1JXb08wVGZrMHNZVDhmcTNONnNkcDU4VkFwX2JncUkxSkhqN0o3aEE?oc=5","date":"2026-02-19","type":"pipeline","source":"Spencer Fane","summary":"Congress Enacts Long-Awaited Fix to Orphan Drug Exclusivity in 2026 Consolidated Appropriations Act - Spencer Fane","headline":"Congress Enacts Long-Awaited Fix to Orphan Drug Exclusivity in 2026 Consolidated Appropriations Act","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQNmRhZ00wT3VYUmo3Q2pnTnlUS3MzbXRQM0Y0R1BleWtLUU1zZHdiOWRDMXZGRzNwaWJiTGlRQml4d1NKTWUzWlVjZ2VfWE4wU3Bac1lSSHRQMUFhd3o1VzhXWWN3UGJhbGVnX0F2aFRySW9fS1NJVWNVNzBjMVo3MnlXRjlIQjRBUk5TaU5RcEJOamtROGZkWklfaDJwWWVyNTN6Q042c3U3a1lvekNzZ3NUMGtOX1BDdGhtYzV1a3ZBZGFKaFZuTFkxWGo?oc=5","date":"2026-01-12","type":"pipeline","source":"PR Newswire","summary":"Neurelis Provides Business Update Highlighting Transformational 2025 Results - PR Newswire","headline":"Neurelis Provides Business Update Highlighting Transformational 2025 Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQQjRvNy1HZ1liaFF5NWJTdDRuTVNYeTVqWTV5b2NWeGZIZlNpVEVXOHIwZVhYbDZSQ0VjVUpFUFJ4YzZBaHZDUzhqSXBWUlBkUTFSXy15UURDOWNxSEFBZlZuc2tHYWpqSmJXMHlwRGMyM3VGYXBlWTlvWW1kY1duaklMbUswOGdZSEZ4d2ZLVzh2SzQwNlpQb2ZtX0ZLWmFmUy00ZkZKQ3ZUTGVKenJjWDVJUlhuLWY5UDU0VmZoa2lVR2VudUwxR3F6UEFxZw?oc=5","date":"2025-12-05","type":"trial","source":"PR Newswire","summary":"NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING - PR Newswire","headline":"NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNcUhYVXg1Z3p3Vmk4Y0NSakFDVGc2YUlDeDc1QnVNNE9LQl9rVmhwaU1JbXRHbGVEWlNjNkVCM0pBbUNPX1V0TFcyYkFzemN1aE5IdG1ic1NVOVZTeUJqQ0hkZHJ3a2d3ajNkT3Nya3JMdE1pSmFjSHZGenBSREV6MmFEdVVIMlhzTFJPUkpDbE11VmYteFJpM1BQTEFhTjN1TlJHTFNwQldKb0NRRHc0SF9XUVdIRHZYbzlPOVhrT2plS2UxV0NhblgxWQ?oc=5","date":"2025-04-16","type":"regulatory","source":"Pharmacy Times","summary":"Diazepam Nasal Spray Receives FDA Approval for Seizure Clusters in Individuals 2 Years and Older - Pharmacy Times","headline":"Diazepam Nasal Spray Receives FDA Approval for Seizure Clusters in Individuals 2 Years and Older","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPVzFZVUdYdDhhenVIaWpSelpOSnBYTlpNUkllblJLaDltX3lBWEFHYWsyNC1laUF3aWxjWkZ0X1lWSEdKdWVUVVFHMDAxQmVib2h4RGZ0Yno5VWg1VndySkxQR094NkE5MF9uYjllM01qTmxiOWl5R2R4cHQ2ZmY4Szk1Rkd0a28yVnY2UDgzdXEwd1lwWWEzeXUzaHhPVnJsUk5ULVNsR0NSVUpqUXBxMzkycTRQMzM5Y2lnSzFmM1RILVFWajQwQ0NXTGIwQ2pUMldQeFZIVE43TF9hT2x0aml2c2lyRndBN2dWTUMwUkIzYXRncm80TUJlS3U?oc=5","date":"2025-04-16","type":"regulatory","source":"PR Newswire","summary":"NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 - PR Newswire","headline":"NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNbnVVY3VjWmVLTmM4Qk9RbU9zaE1VOG5PNlU4Z1BFcXBLUDJMV2IzUFhjQ1ZNTDVFVVpZb0w3R3dhOWdROXd2aXpjZ3dwRWk4R3dwLXFfc0EzTGFkQ3ZjQkxfazNEMGczVHVFNGZNdEt4WGczLUhfM2tmcGt4bGxiZjJzUjBueFda?oc=5","date":"2025-03-25","type":"earnings","source":"Precedence Research","summary":"Acute Repetitive Seizures Market Revenue to Attain USD 9.39 Bn by 2033 - Precedence Research","headline":"Acute Repetitive Seizures Market Revenue to Attain USD 9.39 Bn by 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPd3Q4RV9MWjVMbWExOUtEUHJKMXJhMlQybGtPZEs2U0VjYWtfcGJDYTVnMkprVzJwRFBQT2prZUtleF9fVms0YnZNeDFGR2FCWl9zNnBfSVk5WE9EN1EwNVZjd0RFRWJ1Y2lmOEhNWUNZdmF0eDUtSkpvVDUta21GbVQ0THhoZjdQdFBtOFA0TmxWczQ2WVBud1VrYm5qYWEwSXlTcjNOLUhsZlpkSFVNbzZaZk44UExteGlJQjRCXzJkVTBqaG53SUFneXdjdkJSWW53dE9aaG1tYlhCSHNyN2JUc3hPTTk4Ulp0cXc2d21QZ1BNcWVGS1V2TFBQcmkyQ19DSlZ3QQ?oc=5","date":"2025-03-19","type":"regulatory","source":"Psychiatrist.com","summary":"A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Reference Dose of Olanzapine Intramusc","headline":"A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVDlRam9RcVltQm02clJOVWg0THBXTHoxbHRmMEVrUHZGcC1pbElTZ0ZyQlEyWjRZX3Y5RWNkUHdEb2VHN0NaM0wzRnpZUkVSYzVvM3ZwTGNjRVV4RjY3eW9fblZsUzJLWW10SGNSOTJ3NndCbEdtaG1yUk1HdXp5SURraWlKbFhOazRPWm1SM2VHblhfazJWZjhwVWpDY3dOc2hXdzNjNWlyZDFmRFdSRnJId0tBV3ZtN2hjWTJlV0d3WWM?oc=5","date":"2024-11-14","type":"pipeline","source":"PR Newswire","summary":"NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - PR Newswire","headline":"NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1XU0w3Vzd1UXg5bFBHdzZhYmo4eW5nbGt6OFdBYjN4enpudzlKQW04TzM2Zy1OY3F5TXBHTTBEQl9TVjBQQXpSeE85UEVjZ1pjY3RVSDVjM19UQQ?oc=5","date":"2024-07-19","type":"pipeline","source":"Market.us","summary":"Epilepsy Drug Market Size, Share Analysis| CAGR of 4.3% - Market.us","headline":"Epilepsy Drug Market Size, Share Analysis| CAGR of 4.3%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1TMmQyOGFHNFFTVGJnaWFXdUV1bXYyeUVuVzM0amd3ZGNxcnU2SmdGdG50b2w4bm1zZzFTc1V1TExWSDgzQ2hrWmFBUDIxM2Q1THUyZ1Y1LXJSU1BGazRWTEUyTHJKQXhGTkhpaTUzV0k1c252TzFYYnZvMFJ6SHM?oc=5","date":"2022-12-08","type":"regulatory","source":"Drug Delivery Business","summary":"FDA accepts NDA for intranasal epinephrine from ARS Pharmaceuticals - Drug Delivery Business","headline":"FDA accepts NDA for intranasal epinephrine from ARS Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1LemtzZ3VacVZ6UERiM2ZTT3VmcTl1dW9CcGg1ZFZmQWpYLXFIc2ZZNDBzX0VaNnVROWRKTUlyb2dUVkpvSVkyWTBJcm9tQWZNSmFKSXAxVjJYb0xJWmI2Qll3NXA5NlFFdUlicThB?oc=5","date":"2021-03-10","type":"pipeline","source":"MassDevice","summary":"Neurelis closes $114M Series D for diazepam nasal spray - MassDevice","headline":"Neurelis closes $114M Series D for diazepam nasal spray","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}